tiprankstipranks
Telix Pharmaceuticals Ltd. (TLPPF)
OTHER OTC:TLPPF
US Market
TLPPF
Telix Pharmaceuticals
RESEARCH TOOLSreports

Telix Pharmaceuticals (TLPPF) Stock Forecast & Price Target

188 Followers
See the Price Targets and Ratings of:

TLPPF Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Telix
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TLPPF Stock 12 Month Forecast

Average Price Target

$18.03
▲(72.03% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Telix Pharmaceuticals in the last 3 months. The average price target is $18.03 with a high forecast of $22.20 and a low forecast of $13.61. The average price target represents a 72.03% change from the last price of $10.48.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","14":"$14","23":"$23","9.5":"$9.5","18.5":"$18.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":22.2022,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$22.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.028345555555557,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.6078,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.5,14,18.5,23],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.865,10.814015384615384,11.76303076923077,12.712046153846154,13.661061538461539,14.610076923076925,15.559092307692309,16.508107692307693,17.45712307692308,18.40613846153846,19.355153846153847,20.304169230769233,21.25318461538462,{"y":22.2022,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.865,10.492949658119658,11.120899316239317,11.748848974358975,12.376798632478632,13.004748290598291,13.632697948717949,14.260647606837608,14.888597264957266,15.516546923076923,16.144496581196584,16.77244623931624,17.4003958974359,{"y":18.028345555555557,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.865,10.152907692307693,10.440815384615385,10.728723076923076,11.016630769230769,11.304538461538462,11.592446153846154,11.880353846153845,12.168261538461538,12.45616923076923,12.744076923076923,13.031984615384616,13.319892307692307,{"y":13.6078,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.25,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.585,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.23,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.875,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.865,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$22.20Average Price Target$18.03Lowest Price Target$13.61
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on TLPPF
David Stanton
Jefferies
Jefferies
$20.77→$20.98
Buy
100.24%
Upside
Reiterated
08/21/26
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Takeda Pharmaceutical Co (Other OTC: TKPHF)
Jarden Analyst forecast on TLPPF
Steven Wheen
Jarden
Jarden
$15.11→$14.83
Buy
41.46%
Upside
Reiterated
08/21/26
Jarden Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Morgan Stanley Analyst forecast on TLPPF
David Bailey
Morgan Stanley
Morgan Stanley
$17.12
Buy
63.33%
Upside
Reiterated
08/21/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Telix Pharmaceuticals (Other OTC: TLPPF)
Bell Potter Analyst forecast on TLPPF
John Hester
Bell Potter
Bell Potter
$13.61
Buy
29.85%
Upside
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF), CSL (Other OTC: CMXHF) and Sol-Gel Technologies (NASDAQ: SLGL)
Canaccord Genuity Analyst forecast on TLPPF
Shane Storey
Canaccord Genuity
Canaccord Genuity
$21.49→$20.23
Buy
93.06%
Upside
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Ansell (Other OTC: ANSLF)
Citi Analyst forecast on TLPPF
Laura Sutcliffe
Citi
Citi
$22.2
Buy
111.85%
Upside
Reiterated
08/20/26
Telix Pharmaceuticals: Buy Rating Reiterated with Unchanged $31 Target Ahead of Key Pixclara Regulatory Catalyst
RBC Capital Analyst forecast on TLPPF
Craig Wong-Pan
RBC Capital
RBC Capital
$12.89→$13.61
Hold
29.85%
Upside
Reiterated
08/20/26
RBC Capital Reaffirms Their Hold Rating on Telix Pharmaceuticals (TLPPF)
J.P. Morgan Analyst forecast on TLPPF
Chris Cooper
J.P. Morgan
J.P. Morgan
$17.48
Buy
66.75%
Upside
Reiterated
07/23/26
J.P. Morgan Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
UBS Analyst forecast on TLPPF
David Dai
UBS
UBS
$22.2
Buy
111.85%
Upside
Reiterated
07/01/26
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN) and Telix Pharmaceuticals (Other OTC: TLPPF)
TD Cowen Analyst forecast on TLPPF
Tara Bancroft
TD Cowen
TD Cowen
$14.32
Buy
36.68%
Upside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
Ord Minnett Analyst forecast on TLPPF
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$16.19
Buy
54.45%
Upside
Reiterated
10/15/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett
CLSA Analyst forecast on TLPPF
Andrew Paine
CLSA
CLSA
$17.37
Buy
65.72%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on TLPPF
David Stanton
Jefferies
Jefferies
$20.77→$20.98
Buy
100.24%
Upside
Reiterated
08/21/26
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Takeda Pharmaceutical Co (Other OTC: TKPHF)
Jarden Analyst forecast on TLPPF
Steven Wheen
Jarden
Jarden
$15.11→$14.83
Buy
41.46%
Upside
Reiterated
08/21/26
Jarden Keeps Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Morgan Stanley Analyst forecast on TLPPF
David Bailey
Morgan Stanley
Morgan Stanley
$17.12
Buy
63.33%
Upside
Reiterated
08/21/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) and Telix Pharmaceuticals (Other OTC: TLPPF)
Bell Potter Analyst forecast on TLPPF
John Hester
Bell Potter
Bell Potter
$13.61
Buy
29.85%
Upside
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF), CSL (Other OTC: CMXHF) and Sol-Gel Technologies (NASDAQ: SLGL)
Canaccord Genuity Analyst forecast on TLPPF
Shane Storey
Canaccord Genuity
Canaccord Genuity
$21.49→$20.23
Buy
93.06%
Upside
Reiterated
08/20/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Telix Pharmaceuticals (Other OTC: TLPPF) and Ansell (Other OTC: ANSLF)
Citi Analyst forecast on TLPPF
Laura Sutcliffe
Citi
Citi
$22.2
Buy
111.85%
Upside
Reiterated
08/20/26
Telix Pharmaceuticals: Buy Rating Reiterated with Unchanged $31 Target Ahead of Key Pixclara Regulatory Catalyst
RBC Capital Analyst forecast on TLPPF
Craig Wong-Pan
RBC Capital
RBC Capital
$12.89→$13.61
Hold
29.85%
Upside
Reiterated
08/20/26
RBC Capital Reaffirms Their Hold Rating on Telix Pharmaceuticals (TLPPF)
J.P. Morgan Analyst forecast on TLPPF
Chris Cooper
J.P. Morgan
J.P. Morgan
$17.48
Buy
66.75%
Upside
Reiterated
07/23/26
J.P. Morgan Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)
UBS Analyst forecast on TLPPF
David Dai
UBS
UBS
$22.2
Buy
111.85%
Upside
Reiterated
07/01/26
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (NYSE: EVMN) and Telix Pharmaceuticals (Other OTC: TLPPF)
TD Cowen Analyst forecast on TLPPF
Tara Bancroft
TD Cowen
TD Cowen
$14.32
Buy
36.68%
Upside
Reiterated
02/19/26
Telix: Dual-Product PSMA Strategy and Cash-Generating Diagnostics Base Support Buy Rating and Multibillion-Dollar Therapeutics Upside
Ord Minnett Analyst forecast on TLPPF
Unknown Analyst
Ord Minnett
Not Ranked
Ord Minnett
$16.19
Buy
54.45%
Upside
Reiterated
10/15/25
Telix Pharmaceuticals (TLPPF) Gets a Buy from Ord Minnett
CLSA Analyst forecast on TLPPF
Andrew Paine
CLSA
CLSA
$17.37
Buy
65.72%
Upside
Reiterated
10/03/25
CLSA Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Telix Pharmaceuticals

3 Months
David StantonJefferies
Success Rate
14/19 ratings generated profit
74%
Average Return
+23.42%
Copying David Stanton's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +23.42% per trade.
1 Year
Steven WheenJarden
Success Rate
19/27 ratings generated profit
70%
Average Return
+45.08%
Copying Steven Wheen's trades and holding each position for 1 Year would result in 70.37% of your transactions generating a profit, with an average return of +45.08% per trade.
2 Years
Steven WheenJarden
Success Rate
16/27 ratings generated profit
59%
Average Return
+83.87%
Copying Steven Wheen's trades and holding each position for 2 Years would result in 59.26% of your transactions generating a profit, with an average return of +83.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TLPPF Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
31
24
15
14
15
Buy
4
5
5
4
4
Hold
0
0
0
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
35
29
20
20
22
In the current month, TLPPF has received 19 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. TLPPF average Analyst price target in the past 3 months is 18.03.
Each month's total comprises the sum of three months' worth of ratings.

TLPPF Financial Forecast

TLPPF Earnings Forecast

Next quarter’s earnings estimate for TLPPF is $0.01 with a range of -$0.04 to $0.08. The previous quarter’s EPS was $0.17. TLPPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TLPPF has Performed in-line its overall industry.
Next quarter’s earnings estimate for TLPPF is $0.01 with a range of -$0.04 to $0.08. The previous quarter’s EPS was $0.17. TLPPF beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year TLPPF has Performed in-line its overall industry.

TLPPF Sales Forecast

Next quarter’s sales forecast for TLPPF is $493.27M with a range of $480.30M to $502.30M. The previous quarter’s sales results were $487.58M. TLPPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TLPPF has Performed in-line its overall industry.
Next quarter’s sales forecast for TLPPF is $493.27M with a range of $480.30M to $502.30M. The previous quarter’s sales results were $487.58M. TLPPF beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year TLPPF has Performed in-line its overall industry.

TLPPF Stock Forecast FAQ

What is TLPPF’s average 12-month price target, according to analysts?
Based on analyst ratings, Telix Pharmaceuticals Ltd.’s 12-month average price target is 18.03.
    What is TLPPF’s upside potential, based on the analysts’ average price target?
    Telix Pharmaceuticals Ltd. has 72.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TLPPF a Buy, Sell or Hold?
          Telix Pharmaceuticals Ltd. has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Telix Pharmaceuticals Ltd.’s price target?
            The average price target for Telix Pharmaceuticals Ltd. is 18.03. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $22.20 ,the lowest forecast is $13.61. The average price target represents 72.03% Increase from the current price of $10.48.
              What do analysts say about Telix Pharmaceuticals Ltd.?
              Telix Pharmaceuticals Ltd.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of TLPPF?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.